125 related articles for article (PubMed ID: 9057086)
21. Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks.
Clarke DJ; Johnson RT; Downes CS
J Cell Sci; 1993 Jun; 105 ( Pt 2)():563-9. PubMed ID: 8408285
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
[TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
24. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
Muñoz P; Baus F; Piette J
Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of topoisomerase II by ICRF-193 prevents efficient replication of herpes simplex virus type 1.
Hammarsten O; Yao X; Elias P
J Virol; 1996 Jul; 70(7):4523-9. PubMed ID: 8676478
[TBL] [Abstract][Full Text] [Related]
27. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.
Campbell KJ; O'Shea JM; Perkins ND
BMC Cancer; 2006 Apr; 6():101. PubMed ID: 16630341
[TBL] [Abstract][Full Text] [Related]
28. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II poisoning by ICRF-193.
Huang KC; Gao H; Yamasaki EF; Grabowski DR; Liu S; Shen LL; Chan KK; Ganapathi R; Snapka RM
J Biol Chem; 2001 Nov; 276(48):44488-94. PubMed ID: 11577077
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
31. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
[TBL] [Abstract][Full Text] [Related]
32. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16).
Sehested M; Jensen PB; Sørensen BS; Holm B; Friche E; Demant EJ
Biochem Pharmacol; 1993 Aug; 46(3):389-93. PubMed ID: 8394080
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193.
Oestergaard VH; Knudsen BR; Andersen AH
J Biol Chem; 2004 Jul; 279(27):28100-5. PubMed ID: 15123716
[TBL] [Abstract][Full Text] [Related]
34. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
[TBL] [Abstract][Full Text] [Related]
35. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells.
Yang HL; Dong YB; Elliott MJ; Wong SL; McMasters KM
Cancer Gene Ther; 2001 Apr; 8(4):241-51. PubMed ID: 11393276
[TBL] [Abstract][Full Text] [Related]
36. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
37. Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells.
Torres R; Calle C; Aller P; Mata F
Mol Cell Biochem; 2000 May; 208(1-2):157-62. PubMed ID: 10939640
[TBL] [Abstract][Full Text] [Related]
38. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
40. Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Tabata M; Tabata R; Grabowski DR; Bukowski RM; Ganapathi MK; Ganapathi R
J Biol Chem; 2001 Mar; 276(11):8029-36. PubMed ID: 11115510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
